Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Public ClinicalTrials.gov record NCT03755791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
Study identification
- NCT ID
- NCT03755791
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 837 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2018
- Primary completion
- Nov 29, 2021
- Completion
- Jul 30, 2026
- Last update posted
- Dec 10, 2025
2018 – 2026
United States locations
- U.S. sites
- 33
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #208 | Phoenix | Arizona | 85004 | — |
| Exelixis Clinical Site #159 | Tucson | Arizona | 85719 | — |
| Exelixis Clinical Site #44 | La Jolla | California | 92037 | — |
| Exelixis Clinical Site #112 | Los Angeles | California | 90033 | — |
| Exelixis Clinical Site #200 | Orange | California | 92868-3201 | — |
| Exelixis Clinical Site #2 | Rialto | California | 92377 | — |
| Exelixis Clinical Site #207 | San Diego | California | 92093 | — |
| Exelixis Clinical Site #109 | San Francisco | California | 94115 | — |
| Exelixis Clinical Site #54 | San Francisco | California | 94158 | — |
| Exelixis Clinical Site #58 | Washington D.C. | District of Columbia | 20007 | — |
| Exelixis Clinical Site #191 | Miami | Florida | 33125 | — |
| Exelixis Clinical Site #4 | Atlanta | Georgia | 30318 | — |
| Exelixis Clinical Site #195 | Chicago | Illinois | 60612 | — |
| Exelixis Clinical Site #120 | Chicago | Illinois | 60637 | — |
| Exelixis Clinical Site #6 | Baltimore | Maryland | 21202 | — |
| Exelixis Clinical Site #7 | Burlington | Massachusetts | 01805 | — |
| Exelixis Clinical Site #11 | Kansas City | Missouri | 64128 | — |
| Exelixis Clinical Site #5 | Kansas City | Missouri | 64131 | — |
| Exelixis Clinical Site #8 | St Louis | Missouri | 63110 | — |
| Exelixis Clinical Site #1 | Las Vegas | Nevada | 89169 | — |
| Exelixis Clinical Site #14 | New Brunswick | New Jersey | 08903 | — |
| Exelixis Clinical Site #76 | Albuquerque | New Mexico | 87131 | — |
| Exelixis Clinical Site #12 | Chapel Hill | North Carolina | 27599-7600 | — |
| Exelixis Clinical Site #39 | Toledo | Ohio | 43614 | — |
| Exelixis Clinical Site #176 | Portland | Oregon | 97213 | — |
| Exelixis Clinical Site #88 | Philadelphia | Pennsylvania | 19107 | — |
| Exelixis Clinical Site #144 | Charleston | South Carolina | 29425 | — |
| Exelixis Clinical Site #199 | Dallas | Texas | 75246 | — |
| Exelixis Clinical Site #154 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #19 | Temple | Texas | 76508 | — |
| Exelixis Clinical Site #13 | Seattle | Washington | 98101 | — |
| Exelixis Clinical Site #46 | Seattle | Washington | 98109 | — |
| Exelixis Clinical Site #3 | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 212 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03755791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03755791 live on ClinicalTrials.gov.